Barry Ticho Sells 6,471 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 6,471 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the transaction, the insider now owns 25,782 shares in the company, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Monday, June 2nd, Barry Ticho sold 1,745 shares of Stoke Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $17,450.00.
• On Tuesday, March 18th, Barry Ticho sold 3,884 shares of Stoke Therapeutics stock. The shares were sold at an average price of $8.67, for a total value of $33,674.28.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK traded up $0.26 during mid-day trading on Friday, reaching $11.14. 463,035 shares of the company's stock were exchanged, compared to its average volume of 705,353. The firm has a market capitalization of $608.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.09. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $17.58. The firm has a 50-day moving average price of $8.77 and a two-hundred day moving average price of $9.64.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock worth $220,000 after acquiring an additional 4,512 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Stoke Therapeutics in the 4th quarter worth about $1,423,000. Bank of New York Mellon Corp increased its holdings in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock worth $1,028,000 after acquiring an additional 1,330 shares during the last quarter. Rhumbline Advisers increased its holdings in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock worth $545,000 after acquiring an additional 2,787 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Stoke Therapeutics in the 4th quarter worth about $139,000.

Analyst Ratings Changes

Several brokerages have weighed in on STOK. Chardan Capital restated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. HC Wainwright dropped their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of "Buy" and an average target price of $23.20.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.